Theoretically, the monoclonal antibody against IL-6, tocilizumab, could have an anti-inflammatory effect in NASH, as it is effective against hyperinflammatory states of COVID-19, but it has also demonstrated liver enzyme elevations and DILI in a few cases [55]. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatohepatitis.